|
|
| Nomenclature |
|
Symbol:
|
Tg(tetO-APPSwInd)885Dbo
|
|
Name:
|
transgene insertion 885, David R Borchelt
|
|
MGI ID: |
MGI:3639702 |
|
Synonyms: |
TetAPPswe/ind line 885 |
|
Transgene:
|
Tg(tetO-APPSwInd)885Dbo
Location:
unknown
|
|
Transgene
origin |
|
Strain of Origin:
|
(C57BL/6J x C3H/HeJ)F2
|
|
Transgene
description |
|
Transgene
Type: | |
Transgenic (random, expressed) |
|
Mutation: | |
Insertion |
| |
|
Mutation details: The transgene expresses the mutant human amyloid protein precursor APPSwInd, which bears both the Swedish (K670N/M671L) and the Indiana (V717F) mutations, under the control of the tetracycline-responsive element (tetO). When bred to another transgenic mouse expressing reverse tertracyclin-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (fTA) to creat a bitransgenic animal, tissue APPSwInd transgene expression can be regulated with the tetracycline analog, doxycycline. These double transgenic show the highest APPSwInd expression and have the highest doxycycline requirements for suppression of transgene expression.
(J:80782, J:109829)
|
|
Phenotypes
|
View phenotypes for all genotypes (concatenated display).
|
| Find Mice (IMSR) |
Mouse strains and cell lines available from the
International Mouse Strain Resource
(IMSR)
|
|
Notes |
Founder line 8-85 is the highest expressing line, and is representative of a number of lines made with this construct.
|
| References |
|
Original: |
J:109829
Jankowsky JL et al.,
"Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease."
PLoS Med 2005 Dec;2(12):e355
|
|
All: |
5 reference(s)
|
|
Analysis Tools
